Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
47
LCTX Quote, Financials, Valuation and Earnings
Last price:
$1.68
Seasonality move
:
11.05%
Day range:
$1.63 - $1.72
52-week range:
$0.37 - $2.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
34.67x
P/B ratio:
17.35x
Volume:
1.8M
Avg. volume:
1.9M
1-year change:
202.64%
Market cap:
$382.3M
Revenue:
$9.5M
EPS (TTM):
-$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics, Inc.
|
$2.3M | -$0.03 | -31.68% | -192.77% | $4.17 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
BLTE
Belite Bio, Inc.
|
-- | -$0.49 | -- | -58.83% | $184.33 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
OCGN
Ocugen, Inc.
|
$440K | -$0.06 | 12.57% | -20.55% | $9.00 |
|
PROK
ProKidney Corp.
|
$44.3K | -$0.14 | -100% | -9.1% | $6.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics, Inc.
|
$1.66 | $4.17 | $382.3M | -- | $0.00 | 0% | 34.67x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
BLTE
Belite Bio, Inc.
|
$154.42 | $184.33 | $5.8B | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI Corp.
|
$4.44 | $42.50 | $13.5M | -- | $0.00 | 0% | -- |
|
OCGN
Ocugen, Inc.
|
$1.40 | $9.00 | $437.2M | -- | $0.00 | 0% | 76.84x |
|
PROK
ProKidney Corp.
|
$2.50 | $6.50 | $353.9M | -- | $0.00 | 0% | 439.14x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics, Inc.
|
10.63% | 5.454 | 0.68% | 4.39x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
BLTE
Belite Bio, Inc.
|
0.19% | -0.369 | 0.02% | 34.17x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
OCGN
Ocugen, Inc.
|
90.32% | 2.409 | 6.48% | 1.60x |
|
PROK
ProKidney Corp.
|
-0.42% | 4.680 | 0.26% | 9.35x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LCTX
Lineage Cell Therapeutics, Inc.
|
$3.5M | -$3.8M | -112.65% | -117.46% | -102.85% | -$3.6M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
BLTE
Belite Bio, Inc.
|
-$347K | -$23M | -37.09% | -37.13% | -- | -- |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
OCGN
Ocugen, Inc.
|
$802K | -$17.6M | -139.38% | -345.08% | -1005.99% | -$13M |
|
PROK
ProKidney Corp.
|
-$1.2M | -$38.5M | -42.03% | -42.51% | -17759.91% | -$31.8M |
Lineage Cell Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns LCTX or AIM?
AIM ImmunoTech has a net margin of -808.26% compared to Lineage Cell Therapeutics, Inc.'s net margin of -10571.43%. Lineage Cell Therapeutics, Inc.'s return on equity of -117.46% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital LCTXLineage Cell Therapeutics, Inc.95.03% -$0.13 $23.4M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About LCTX or AIM?
Lineage Cell Therapeutics, Inc. has a consensus price target of $4.17, signalling upside risk potential of 151%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Lineage Cell Therapeutics, Inc., analysts believe AIM ImmunoTech is more attractive than Lineage Cell Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LCTXLineage Cell Therapeutics, Inc.5 1 0 AIMAIM ImmunoTech1 0 0 -
Is LCTX or AIM More Risky?
Lineage Cell Therapeutics, Inc. has a beta of 1.776, which suggesting that the stock is 77.601% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock LCTX or AIM?
Lineage Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LCTX or AIM?
Lineage Cell Therapeutics, Inc. quarterly revenues are $3.7M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Lineage Cell Therapeutics, Inc.'s net income of -$29.8M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics, Inc. is 34.67x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LCTXLineage Cell Therapeutics, Inc.34.67x -- $3.7M -$29.8M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns LCTX or BLTE?
Belite Bio, Inc. has a net margin of -808.26% compared to Lineage Cell Therapeutics, Inc.'s net margin of --. Lineage Cell Therapeutics, Inc.'s return on equity of -117.46% beat Belite Bio, Inc.'s return on equity of -37.13%.
Company Gross Margin Earnings Per Share Invested Capital LCTXLineage Cell Therapeutics, Inc.95.03% -$0.13 $23.4M BLTEBelite Bio, Inc.-- -$0.65 $274.6M -
What do Analysts Say About LCTX or BLTE?
Lineage Cell Therapeutics, Inc. has a consensus price target of $4.17, signalling upside risk potential of 151%. On the other hand Belite Bio, Inc. has an analysts' consensus of $184.33 which suggests that it could grow by 18.55%. Given that Lineage Cell Therapeutics, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Lineage Cell Therapeutics, Inc. is more attractive than Belite Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LCTXLineage Cell Therapeutics, Inc.5 1 0 BLTEBelite Bio, Inc.5 0 0 -
Is LCTX or BLTE More Risky?
Lineage Cell Therapeutics, Inc. has a beta of 1.776, which suggesting that the stock is 77.601% more volatile than S&P 500. In comparison Belite Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LCTX or BLTE?
Lineage Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Belite Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics, Inc. pays -- of its earnings as a dividend. Belite Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LCTX or BLTE?
Lineage Cell Therapeutics, Inc. quarterly revenues are $3.7M, which are larger than Belite Bio, Inc. quarterly revenues of --. Lineage Cell Therapeutics, Inc.'s net income of -$29.8M is lower than Belite Bio, Inc.'s net income of -$21.7M. Notably, Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while Belite Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics, Inc. is 34.67x versus -- for Belite Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LCTXLineage Cell Therapeutics, Inc.34.67x -- $3.7M -$29.8M BLTEBelite Bio, Inc.-- -- -- -$21.7M
-
Which has Higher Returns LCTX or CVM?
CEL-SCI Corp. has a net margin of -808.26% compared to Lineage Cell Therapeutics, Inc.'s net margin of --. Lineage Cell Therapeutics, Inc.'s return on equity of -117.46% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital LCTXLineage Cell Therapeutics, Inc.95.03% -$0.13 $23.4M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About LCTX or CVM?
Lineage Cell Therapeutics, Inc. has a consensus price target of $4.17, signalling upside risk potential of 151%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 857.21%. Given that CEL-SCI Corp. has higher upside potential than Lineage Cell Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Lineage Cell Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LCTXLineage Cell Therapeutics, Inc.5 1 0 CVMCEL-SCI Corp.1 0 0 -
Is LCTX or CVM More Risky?
Lineage Cell Therapeutics, Inc. has a beta of 1.776, which suggesting that the stock is 77.601% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock LCTX or CVM?
Lineage Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LCTX or CVM?
Lineage Cell Therapeutics, Inc. quarterly revenues are $3.7M, which are larger than CEL-SCI Corp. quarterly revenues of --. Lineage Cell Therapeutics, Inc.'s net income of -$29.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics, Inc. is 34.67x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LCTXLineage Cell Therapeutics, Inc.34.67x -- $3.7M -$29.8M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns LCTX or OCGN?
Ocugen, Inc. has a net margin of -808.26% compared to Lineage Cell Therapeutics, Inc.'s net margin of -1144.46%. Lineage Cell Therapeutics, Inc.'s return on equity of -117.46% beat Ocugen, Inc.'s return on equity of -345.08%.
Company Gross Margin Earnings Per Share Invested Capital LCTXLineage Cell Therapeutics, Inc.95.03% -$0.13 $23.4M OCGNOcugen, Inc.45.78% -$0.07 $36.5M -
What do Analysts Say About LCTX or OCGN?
Lineage Cell Therapeutics, Inc. has a consensus price target of $4.17, signalling upside risk potential of 151%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 542.86%. Given that Ocugen, Inc. has higher upside potential than Lineage Cell Therapeutics, Inc., analysts believe Ocugen, Inc. is more attractive than Lineage Cell Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LCTXLineage Cell Therapeutics, Inc.5 1 0 OCGNOcugen, Inc.3 0 0 -
Is LCTX or OCGN More Risky?
Lineage Cell Therapeutics, Inc. has a beta of 1.776, which suggesting that the stock is 77.601% more volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 4.540, suggesting its more volatile than the S&P 500 by 354.007%.
-
Which is a Better Dividend Stock LCTX or OCGN?
Lineage Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LCTX or OCGN?
Lineage Cell Therapeutics, Inc. quarterly revenues are $3.7M, which are larger than Ocugen, Inc. quarterly revenues of $1.8M. Lineage Cell Therapeutics, Inc.'s net income of -$29.8M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics, Inc. is 34.67x versus 76.84x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LCTXLineage Cell Therapeutics, Inc.34.67x -- $3.7M -$29.8M OCGNOcugen, Inc.76.84x -- $1.8M -$20.1M
-
Which has Higher Returns LCTX or PROK?
ProKidney Corp. has a net margin of -808.26% compared to Lineage Cell Therapeutics, Inc.'s net margin of -16517.51%. Lineage Cell Therapeutics, Inc.'s return on equity of -117.46% beat ProKidney Corp.'s return on equity of -42.51%.
Company Gross Margin Earnings Per Share Invested Capital LCTXLineage Cell Therapeutics, Inc.95.03% -$0.13 $23.4M PROKProKidney Corp.-544.24% -$0.12 $322.6M -
What do Analysts Say About LCTX or PROK?
Lineage Cell Therapeutics, Inc. has a consensus price target of $4.17, signalling upside risk potential of 151%. On the other hand ProKidney Corp. has an analysts' consensus of $6.50 which suggests that it could grow by 160%. Given that ProKidney Corp. has higher upside potential than Lineage Cell Therapeutics, Inc., analysts believe ProKidney Corp. is more attractive than Lineage Cell Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LCTXLineage Cell Therapeutics, Inc.5 1 0 PROKProKidney Corp.4 3 0 -
Is LCTX or PROK More Risky?
Lineage Cell Therapeutics, Inc. has a beta of 1.776, which suggesting that the stock is 77.601% more volatile than S&P 500. In comparison ProKidney Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LCTX or PROK?
Lineage Cell Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProKidney Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lineage Cell Therapeutics, Inc. pays -- of its earnings as a dividend. ProKidney Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LCTX or PROK?
Lineage Cell Therapeutics, Inc. quarterly revenues are $3.7M, which are larger than ProKidney Corp. quarterly revenues of $217K. Lineage Cell Therapeutics, Inc.'s net income of -$29.8M is higher than ProKidney Corp.'s net income of -$35.8M. Notably, Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio is -- while ProKidney Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lineage Cell Therapeutics, Inc. is 34.67x versus 439.14x for ProKidney Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LCTXLineage Cell Therapeutics, Inc.34.67x -- $3.7M -$29.8M PROKProKidney Corp.439.14x -- $217K -$35.8M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
